GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (NAS:STIM) » Definitions » Piotroski F-Score

Neuronetics (Neuronetics) Piotroski F-Score

: 3 (As of Today)
View and export this data going back to 2018. Start your Free Trial

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Neuronetics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Neuronetics's Piotroski F-Score or its related term are showing as below:

STIM' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 5
Current: 3

During the past 8 years, the highest Piotroski F-Score of Neuronetics was 5. The lowest was 2. And the median was 3.


Neuronetics Piotroski F-Score Historical Data

The historical data trend for Neuronetics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 5.00 3.00 3.00

Neuronetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 2.00 2.00 3.00

Competitive Comparison

For the Diagnostics & Research subindustry, Neuronetics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuronetics Piotroski F-Score Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Neuronetics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -10.52 + -4.901 + -9.391 + -5.377 = $-30.19 Mil.
Cash Flow from Operations was -15.213 + -8.834 + -10.124 + 2.133 = $-32.04 Mil.
Revenue was 15.54 + 17.61 + 17.884 + 20.314 = $71.35 Mil.
Gross Profit was 11.396 + 12.774 + 11.764 + 15.771 = $51.71 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(116.884 + 103.604 + 100.392 + 92.988 + 115.831) / 5 = $105.9398 Mil.
Total Assets at the begining of this year (Dec22) was $116.88 Mil.
Long-Term Debt & Capital Lease Obligation was $61.63 Mil.
Total Current Assets was $93.79 Mil.
Total Current Liabilities was $19.81 Mil.
Net Income was -10.838 + -10.422 + -7.609 + -8.29 = $-37.16 Mil.

Revenue was 14.181 + 16.329 + 16.498 + 18.198 = $65.21 Mil.
Gross Profit was 10.696 + 12.29 + 12.928 + 13.808 = $49.72 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(141.223 + 129.944 + 122.953 + 119.235 + 116.884) / 5 = $126.0478 Mil.
Total Assets at the begining of last year (Dec21) was $141.22 Mil.
Long-Term Debt & Capital Lease Obligation was $25.80 Mil.
Total Current Assets was $98.77 Mil.
Total Current Liabilities was $33.20 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Neuronetics's current Net Income (TTM) was -30.19. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Neuronetics's current Cash Flow from Operations (TTM) was -32.04. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-30.189/116.884
=-0.25828172

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-37.159/141.223
=-0.26312286

Neuronetics's return on assets of this year was -0.25828172. Neuronetics's return on assets of last year was -0.26312286. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Neuronetics's current Net Income (TTM) was -30.19. Neuronetics's current Cash Flow from Operations (TTM) was -32.04. ==> -32.04 <= -30.19 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=61.629/105.9398
=0.58173604

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=25.796/126.0478
=0.20465252

Neuronetics's gearing of this year was 0.58173604. Neuronetics's gearing of last year was 0.20465252. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=93.793/19.812
=4.73415102

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=98.769/33.199
=2.97505949

Neuronetics's current ratio of this year was 4.73415102. Neuronetics's current ratio of last year was 2.97505949. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Neuronetics's number of shares in issue this year was 29.117. Neuronetics's number of shares in issue last year was 27.209. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=51.705/71.348
=0.72468745

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=49.722/65.206
=0.76253719

Neuronetics's gross margin of this year was 0.72468745. Neuronetics's gross margin of last year was 0.76253719. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=71.348/116.884
=0.61041717

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=65.206/141.223
=0.46172366

Neuronetics's asset turnover of this year was 0.61041717. Neuronetics's asset turnover of last year was 0.46172366. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+1+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Neuronetics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Neuronetics  (NAS:STIM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Neuronetics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Neuronetics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuronetics (Neuronetics) Business Description

Traded in Other Exchanges
Address
3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Executives
Keith J Sullivan director, officer: President and CEO C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
William Andrew Macan officer: Sr. VP, GC, CCO and Secretary 24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Stephen Furlong officer: CFO C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
John K Bakewell director C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc 10 percent owner 245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper director BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook director 162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Glenn P Muir director C/O HOLOGIC, INC., BEDFORD MA 01730
Gregory Harper officer: VP of Prod. Dev. & Operations C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley director 2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie officer: Chief Commercial Officer C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355